Literature DB >> 24103254

Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination.

Cédric M Hysek1, Linda D Simmler1, Nathalie Schillinger1, Nicole Meyer1, Yasmin Schmid1, Massimiliano Donzelli1, Eric Grouzmann2, Matthias E Liechti1.   

Abstract

Methylphenidate and 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') are widely misused psychoactive drugs. Methylphenidate increases brain dopamine and norepinephrine levels by blocking the presynaptic reuptake transporters. MDMA releases serotonin, dopamine and norepinephrine through the same transporters. Pharmacodynamic interactions of methylphenidate and MDMA are likely. This study compared the pharmacodynamic and pharmacokinetic effects of methylphenidate and MDMA administered alone or in combination in healthy subjects using a double-blind, placebo-controlled, crossover design. Methylphenidate did not enhance the psychotropic effects of MDMA, although it produced psychostimulant effects on its own. The haemodynamic and adverse effects of co-administration of methylphenidate and MDMA were significantly higher compared with MDMA or methylphenidate alone. Methylphenidate did not change the pharmacokinetics of MDMA and vice versa. Methylphenidate and MDMA shared some subjective amphetamine-type effects; however, 125 mg of MDMA increased positive mood more than 60 mg of methylphenidate, and methylphenidate enhanced activity and concentration more than MDMA. Methylphenidate and MDMA differentially altered facial emotion recognition. Methylphenidate enhanced the recognition of sad and fearful faces, whereas MDMA reduced the recognition of negative emotions. Additionally, the present study found acute pharmacodynamic tolerance to MDMA but not methylphenidate. In conclusion, the combined use of methylphenidate and MDMA does not produce more psychoactive effects compared with either drug alone, but potentially enhances cardiovascular and adverse effects. The findings may be of clinical importance for assessing the risks of combined psychostimulant misuse. Trial registration identification number: NCT01465685 (http://clinicaltrials.gov/ct2/show/NCT01465685).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24103254     DOI: 10.1017/S1461145713001132

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  47 in total

Review 1.  The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals.

Authors:  Philip Kamilar-Britt; Gillinder Bedi
Journal:  Neurosci Biobehav Rev       Date:  2015-09-25       Impact factor: 8.989

Review 2.  Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects.

Authors:  Ricardo Jorge Dinis-Oliveira
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

Review 3.  A review of the effects of nicotine on social functioning.

Authors:  Lea M Martin; Michael A Sayette
Journal:  Exp Clin Psychopharmacol       Date:  2018-06-28       Impact factor: 3.157

4.  Exposure-response analyses of blood pressure and heart rate changes for methylphenidate in healthy adults.

Authors:  Liang Li; Yaning Wang; Ramana S Uppoor; Mehul U Mehta; Tiffany Farchione; Mitchell V Mathis; Hao Zhu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-18       Impact factor: 2.745

5.  Acute effects of lisdexamfetamine and D-amphetamine on social cognition and cognitive performance in a placebo-controlled study in healthy subjects.

Authors:  Patrick C Dolder; Petra Strajhar; Patrick Vizeli; Alex Odermatt; Matthias E Liechti
Journal:  Psychopharmacology (Berl)       Date:  2018-02-09       Impact factor: 4.530

6.  Naltrexone alters the processing of social and emotional stimuli in healthy adults.

Authors:  Margaret C Wardle; Anya K Bershad; Harriet de Wit
Journal:  Soc Neurosci       Date:  2016-01-22       Impact factor: 2.083

7.  Effects of methylphenidate on the aggressive behavior, serotonin and dopamine levels, and dopamine-related gene transcription in brain of male Nile tilapia (Oreochromis niloticus).

Authors:  Isabela Gertrudes Batalhão; Daína Lima; Ana Paula Montedor Russi; Camila Nomura Pereira Boscolo; Danilo Grunig Humberto Silva; Thiago Scremin Boscolo Pereira; Afonso Celso Dias Bainy; Eduardo Alves de Almeida
Journal:  Fish Physiol Biochem       Date:  2019-05-03       Impact factor: 2.794

8.  MDMA alters emotional processing and facilitates positive social interaction.

Authors:  Margaret C Wardle; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2014-04-12       Impact factor: 4.530

Review 9.  Progress and promise for the MDMA drug development program.

Authors:  Allison A Feduccia; Julie Holland; Michael C Mithoefer
Journal:  Psychopharmacology (Berl)       Date:  2017-11-20       Impact factor: 4.530

10.  Regular MDMA use is associated with decreased risk of drug injection among street-involved youth who use illicit drugs.

Authors:  Andrew Gaddis; Stephanie Lake; Kenneth Tupper; Ekaterina Nosova; Katrina Blommaert; Evan Wood; Kora DeBeck
Journal:  Drug Alcohol Depend       Date:  2018-09-12       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.